3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA
(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 11/02/15 -- 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three abstracts at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 5-9 in Boston, Massachusetts.
A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity
Dr. Andrew Brenner, on behalf of all the authors/investigators
Poster Session A
Clinical Trials
Friday, November 6, 2015
12:15 PM - 3:15 PM local time
Exhibit Hall C-D
A54
Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
Poster Session B
Biomarkers
Saturday, November 7, 2015
12:30 PM - 3:30 PM local time
Exhibit Hall C-D
B13
FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640
Poster Session C
Therapeutic Agents: Other
Sunday, November 8, 2015
12:30 PM - 3:30 PM local time
Exhibit Hall C-D
C175
3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in oncology based on expertise in lipid biology. The company's lead oncology product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. Together with a group of world-renowned experts in lipid biology, we have established expertise to translate this biology into patient benefit with a focus on oncology drug development. The company is located in Menlo Park, California.
For additional information on 3-V Biosciences, please visit .
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 5
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2015 - 10:30 Uhr
Sprache: Deutsch
News-ID 431003
Anzahl Zeichen: 0
contact information:
Town:
MENLO PARK, CA
Kategorie:
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA"
steht unter der journalistisch-redaktionellen Verantwortung von
3-V Biosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
